Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program

Warren, E; Anderson, R; Proos, AL; Burnett, LB; Barlow-Stewart, K; Hall, J

Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program

Warren, E Anderson, R Proos, AL Burnett, LB Barlow-Stewart, K Hall, J

Permalink

Publication Type:: Journal Article
Citation:: Genetics in Medicine, 2005, 7 (7), pp. 484 - 494
Issue Date:: 2005-09-01

Closed Access

	Filename	Description	Size
	2005000745OK.pdf		1.11 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Warren, E	en_US
dc.contributor.author	Anderson, R	en_US
dc.contributor.author	Proos, AL	en_US
dc.contributor.author	Burnett, LB	en_US
dc.contributor.author	Barlow-Stewart, K	en_US
dc.contributor.author	Hall, J https://orcid.org/0000-0002-2191-0543	en_US
dc.date.issued	2005-09-01	en_US
dc.identifier.citation	Genetics in Medicine, 2005, 7 (7), pp. 484 - 494	en_US
dc.identifier.issn	1098-3600	en_US
dc.identifier.uri	http://hdl.handle.net/10453/12874
dc.description.abstract	Purpose: To explore the cost-effectiveness of school-based multidisease genetic carrier screening. Method: Decision analysis of the cost-effectiveness of a school-based Tay-Sachs disease and cystic fibrosis genetic carrier screening program, relative to no screening. Data relating to ethnicity profile, test-accepting behavior, and screening program cost were sourced from an existing program in Sydney, Australia. Results: Compared to no screening, the incremental cost-effectiveness of the screening program is A$5,834 per additional carrier detected. This cost-effectiveness ratio is most sensitive to changes in genetic test accuracy, and the cost of laboratory assays. The results imply a cost per affected birth avoided of approximately A$530,000 (≈ US$371,000). Conclusions: This preconceptional genetic carrier screening program offers comparable cost-effectiveness to prenatal screening programs for cystic fibrosis.	en_US
dc.relation.ispartof	Genetics in Medicine	en_US
dc.relation.isbasedon	10.1097/01.gim.0000178496.91670.3b	en_US
dc.subject.classification	Genetics & Heredity	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Cystic Fibrosis	en_US
dc.subject.mesh	Tay-Sachs Disease	en_US
dc.subject.mesh	Adolescent	en_US
dc.subject.mesh	Algorithms	en_US
dc.subject.mesh	Cost-Benefit Analysis	en_US
dc.subject.mesh	Genetic Carrier Screening	en_US
dc.subject.mesh	Genetic Testing	en_US
dc.subject.mesh	Jews	en_US
dc.subject.mesh	Models, Theoretical	en_US
dc.subject.mesh	Schools	en_US
dc.title	Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program	en_US
dc.type	Journal Article
utslib.citation.volume	7	en_US
utslib.for	0604 Genetics	en_US
utslib.for	1103 Clinical Sciences	en_US
dc.location.activity	Aalborg
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Business
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
utslib.copyright.status	closed_access
pubs.issue	7	en_US
pubs.publication-status	Published	en_US
pubs.volume	7	en_US

Abstract:

Purpose: To explore the cost-effectiveness of school-based multidisease genetic carrier screening. Method: Decision analysis of the cost-effectiveness of a school-based Tay-Sachs disease and cystic fibrosis genetic carrier screening program, relative to no screening. Data relating to ethnicity profile, test-accepting behavior, and screening program cost were sourced from an existing program in Sydney, Australia. Results: Compared to no screening, the incremental cost-effectiveness of the screening program is A$5,834 per additional carrier detected. This cost-effectiveness ratio is most sensitive to changes in genetic test accuracy, and the cost of laboratory assays. The results imply a cost per affected birth avoided of approximately A$530,000 (≈ US$371,000). Conclusions: This preconceptional genetic carrier screening program offers comparable cost-effectiveness to prenatal screening programs for cystic fibrosis.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/12874